Pevifoscorvir Sodium's Promising Outcomes from AASLD 2025

Late-breaking AASLD 2025 data show that pevifoscorvir sodium produced sustained antiviral activity at 96 weeks in chronic hepatitis B. The agent achieved durable HBV DNA suppression across enrolled participants in this late-breaking clinical readout.

The most concrete efficacy signal is the magnitude and durability of viral suppression reported in the 96-week results, which documented HBV DNA reductions to below the lower limit of quantification in the majority of HBeAg+ and HBeAg− participants, alongside sustained declines in HBV antigens and HBV RNA.

Clinically, pevifoscorvir sodium's sustained antigen declines and prolonged suppression differ from nucleos(t)ide analogues, which reliably suppress HBV DNA but typically do not lower HBV antigen or cccDNA-associated markers. The observed reductions in antigens and HBV RNA suggest a broader antiviral impact than NA monotherapy.

From a regimen-design perspective, the data support evaluating pevifoscorvir sodium as monotherapy, as a backbone in combination regimens, and in finite-course strategies aimed at durable off-therapy control.